China Center for Drug Evaluation / CDE
The China Center for Drug Evaluation / CDE appears in 130. 谁才是生物医药行业发展的核心驱动力？兼谈创新药产业链的角色分工 as the Chinese drug-review institution in the innovation-drug industry map. The source treats regulators as active industry actors because approval standards, clinical evidence expectations, and registration pathways shape what companies can fund and launch.
156.生物医药的2026：当市场不再为BD躁动，中国药企的星辰大海才刚刚展开 keeps the CDE relevant through Clinical Data Trust Rebuilding and the claim that standards, experience, and clearer clinical expectations have made Chinese data more legible to MNC partners.
Connections
- Food and Drug Administration - U.S. counterpart named in the same source.
- Clinical Development Capability - trials and data packages are built for regulator review.
- Global Pharma Commercialization - global registration capacity as part of MNC capability.
- Clinical Data Trust Rebuilding and Biotech BD Data Validation Phase - episode 156 trial-credibility and follow-up context.